Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
Argus Health
Federal Trade Commission
Johnson and Johnson
Moodys
Baxter
Fuji
UBS
Teva

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,247,416

« Back to Dashboard

Which drugs does patent 8,247,416 protect, and when does it expire?

Patent 8,247,416 protects LYNPARZA and is included in one NDA.

This patent has forty-nine patent family members in thirty-two countries.
Summary for Patent: 8,247,416
Title:Phthalazinone derivative
Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one as crystalline Form A.
Inventor(s): Menear; Keith Allan (Cambridge, GB), Ottridge; Anthony Peter (Cambridge, GB), Londesbrough; Derek John (Sunderland, GB), Hallett; Michael Raymond (Sunderland, GB), Mulholland; Keith Raymond (Macclesfield, GB), Pittam; John David (Macclesfield, GB), Laffan; David Dermot Patrick (Macclesfield, GB), Ashworth; Ian Woodward (Macclesfield, GB), Jones; Martin Francis (Macclesfield, GB), Cherryman; Janette Helen (Macclesfield, GB)
Assignee: Kudos Pharmaceuticals Limited (London, GB)
Application Number:12/500,900
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 8,247,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,247,416

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,692,006 Phthalazinone derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,247,416

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 2064189 ➤ Subscribe
Peru 11752008 ➤ Subscribe
New Zealand 575627 ➤ Subscribe
Norway 20171775 ➤ Subscribe
Norway 20091882 ➤ Subscribe
Malaysia 162829 ➤ Subscribe
Malaysia 147389 ➤ Subscribe
Mexico 2009004103 ➤ Subscribe
South Korea 20140011425 ➤ Subscribe
South Korea 101494910 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
US Department of Justice
Mallinckrodt
Fuji
Citi
Federal Trade Commission
Chinese Patent Office
Chubb
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot